Casley-Smith J R, Casley-Smith J R, Johnson A F, Weston F K
Psychiatry Res. 1986 Jul;18(3):267-73. doi: 10.1016/0165-1781(86)90113-7.
Sixteen chronic schizophrenic subjects were treated for 3 months each with either a benzo-pyrone (Paroven/Venoruton, Zyma) or a placebo in a randomized, double-blind crossover trial. They continued to take their previous drug therapies. Therapeutic effects were measured by the Brief Psychiatric Rating Scale (BPRS), by self-assessment, and by assessment by a relative. Eleven patients completed the trial in relation to BPRS assessment. When on the active substance, as compared with the placebo, they showed a mean improvement of 27% (significant at the 1% level). Ten patients completed the trial in relation to the self and relative's assessments. There were improvements of 16% and 13%, respectively (significant at the 5% levels). Half the patients showed improvements on all the tests. Their improvements were 49%, 31%, and 21%, respectively. There was evidence that the active substance began to have an effect within 2 weeks. No side effects were observed with the active substance.
在一项随机、双盲交叉试验中，16名慢性精神分裂症患者分别接受了为期3个月的苯并吡喃（帕罗文/维脑路通，齐玛公司生产）或安慰剂治疗。他们继续服用之前的药物疗法。通过简明精神病评定量表（BPRS）、自我评估以及亲属评估来衡量治疗效果。11名患者完成了与BPRS评估相关的试验。服用活性物质时，与安慰剂相比，他们的平均改善率为27%（在1%水平上具有显著性）。10名患者完成了与自我和亲属评估相关的试验。改善率分别为16%和13%（在5%水平上具有显著性）。一半的患者在所有测试中均有改善。他们的改善率分别为49%、31%和21%。有证据表明活性物质在2周内开始起作用。服用活性物质未观察到副作用。
